Avidity Biosciences Inc’s recent filing unveils that its Chief Program Officer Gallagher Kathleen P. unloaded Company’s shares for reported $0.19 million on May 01 ’25. In the deal valued at $32.40 per share,5,875 shares were sold. As a result of this transaction, Gallagher Kathleen P. now holds 50,554 shares worth roughly $1.53 million.
Then, KATHLEEN GALLAGHER bought 5,875 shares, generating $191,819 in total proceeds.
Before that, Gallagher Kathleen P. sold 5,875 shares. Avidity Biosciences Inc shares valued at $163,486 were divested by the Chief Program Officer at a price of $27.83 per share. As a result of the transaction, Gallagher Kathleen P. now holds 50,554 shares, worth roughly $1.53 million.
Citigroup initiated its Avidity Biosciences Inc [RNA] rating to a Buy in a research note published on March 13, 2025; the price target was $70. A number of analysts have revised their coverage, including BMO Capital Markets’s analysts, who began to cover the stock in mid March with a ‘”an Outperform”‘ rating. Scotiabank began covering RNA with “Sector outperform” recommendation on March 07, 2025. H.C. Wainwright started covering the stock on December 20, 2024. It rated RNA as “a Buy”.
Price Performance Review of RNA
On Tuesday, Avidity Biosciences Inc [NASDAQ:RNA] saw its stock fall -0.75% to $30.35. Over the last five days, the stock has gained 0.43%. Avidity Biosciences Inc shares have risen nearly 4.37% since the year began. Nevertheless, the stocks have risen 2.46% over the past one year. While a 52-week high of $56.00 was reached on 03/13/25, a 52-week low of $21.51 was recorded on 04/09/25. SMA at 50 days reached $29.48, while 200 days put it at $36.36.
Levels Of Support And Resistance For RNA Stock
The 24-hour chart illustrates a support level at 29.89, which if violated will result in even more drops to 29.43. On the upside, there is a resistance level at 31.05. A further resistance level may holdings at 31.75. The Relative Strength Index (RSI) on the 14-day chart is 52.18, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.02, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 22.92%. Stochastics %K at 77.38% indicates the stock is a holding.
The most recent change occurred on November 26, 2024 when RBC Capital Mkts began covering the stock and recommended ‘”an Outperform”‘ rating along with a $67 price target.
